Therapeutic RSK1 Targeting in Myelofibrosis
NCT07379125
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
18
Enrollment
OTHER
Sponsor class
Conditions
Myelofibrosis
Interventions
DRUG:
PMD-026
Sponsor
Washington University School of Medicine
Collaborators
[object Object]
[object Object]
[object Object]